Skip to main content
Caplight Logo









ChromaTan

ChromaTan

Private
PennsylvaniaHealthcare & Life Scienceshttps://chromatan.com/

Last Round

Grant

Mar 17, 2025

Total Funding Raised

$13.1M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

ChromaTan is a biotechnology company that develops continuous, column-free chromatography solutions for bioprocessing and biologics manufacturing.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Biotechnology, Smart Manufacturing

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

chromatographybioprocessingcontinuous chromatographyCCTCcontinuous countercurrent tangential chromatographydownstream processingbiologics purificationbiomanufacturingsingle-use technologyprocess intensificationbioprocessing hardwarebiotech manufacturingbiotech equipmentCDMOcontract manufacturing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

ChromaTan Comparables

Compare ChromaTan with similar companies based on industry and business-model similarity.

ChromaTan comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
YMC Co., Ltd.
73%
Danaher Corporation
72%
Merck
72%

ChromaTan Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantMar 17, 2025
GrantMay 30, 2024
DebtFeb 6, 2023
GrantSep 21, 2017

Key People

Founding team and executive leadership

Oleg Shinkazh

Founder and CTO

Founding Team

David Fogel

Investor Part Time Chief Financial Officer

Executive Team

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 20, 2026

    Monthly visitors increased 48% MoM.

  • Apr 6, 2026

    Monthly visitors grew 159% MoM, reaching 1.5K.

ChromaTan Filings

Explore SEC and related filing metadata, where available.

ChromaTan filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about ChromaTan's valuation, stock price, and market status.

Is ChromaTan a public or private company?

ChromaTan is a private company.

What is the current stock price of ChromaTan?

ChromaTan is a private company with no public stock price. Caplight tracks ChromaTan's secondary market activity and provides MarketPrice™ estimates to Caplight users.

How much is ChromaTan worth (valuation)?

Valuation information for ChromaTan is not publicly available.

Can I buy ChromaTan stock?

ChromaTan shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was ChromaTan's last funding round?

ChromaTan's most recent funding round was Grant on March 17, 2025.

Who are the main investors in ChromaTan?

Key investors in ChromaTan include Benjamin Franklin Technology Partners, Ben Franklin Technology Partners of Central & Northern PA, Food and Drug Administration, National Institute of General Medical Sciences, Lehigh Valley Angel Investors.

Will ChromaTan IPO soon?

No public IPO plans have been announced for ChromaTan.

How can I track ChromaTan secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ChromaTan's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersPennsylvania
Employee Range12
Year Founded2009
Last FundingMar 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?